Abstract. The fluoroquinolone antibiotic ciprofloxacin has been reported to block delayed rectifier K + channels at much higher concentrations than those at which it exerts its bactericidal activity. In this study using the halothane-anesthetized guinea pig, we assessed whether ciprofloxacin has a proarrhythmic activity. Ciprofloxacin at a clinically relevant dose of 3 mg/kg, i.v. did not affect any electrocardiographic parameters. At 10 mg/kg, it prolonged the QT interval and the duration of the monophasic action potential of the ventricle under sinus rhythm and constant ventricular pacing (n = 6). The extents of its effects on the ventricular repolarization phase were comparable to those of another fluoroquinolone antibiotic moxifloxacin at a clinically relevant dose of 3 mg/kg (n = 6). Meanwhile, the PR interval and QRS width were also increased by ciprofloxacin at 10 mg/kg, suggesting that the drug inhibited cardiac K + channels as well as Na + and Ca 2+ channels in vivo. These results suggest that ciprofloxacin exerted a multi-ion channelblocking action in the heart within the supra-therapeutic dose range. Therefore, careful observation may be necessary for patients with heart disease receiving a higher dose of ciprofloxacin in order to prevent the emergence of resistance.
Introduction
Drug-induced QT interval prolongation is often associated with the onset of torsades de pointes, resulting in life-threatening ventricular arrhythmia, which is closely associated with inhibition of a rapid component of delayed rectifier K + channels (I Kr ) encoded by the human ether-a-go-go-related gene (hERG) (1, 2) . Whereas the fluoroquinolone class of antibacterials is prescribed widely for the treatment of infections, some drugs such as sparfloxacin have been reported to prolong the QT interval in human as well as animal models via inhibition of hERG K + currents (3 -6) . Among the fluoroquinolones, ciprofloxacin was believed to be safer in the early 2000s because no report had linked it to QT-interval prolongation, despite extensive therapeutic use (7) . Indeed, the IC 50 of ciprofloxacin for hERG K + currents has been reported to be 335 mM (111 mg/ml) (7), which is higher than its minimum inhibitory concentration required to inhibit the growth of 90% of organisms (MIC 90 ) for Pseudomonas aeruginosa (32 mg/ml) (8) .
On the other hand, recent clinical reports have suggested that ciprofloxacin may induce QT-interval prolongation or torsades de pointes arrhythmias in the presence or absence of co-administered drugs (9 -11) .
The increasing resistance of bacteria to fluoroquinolone antibiotics is an important clinical problem. To prevent the emergence of resistance, the therapeutic strategy of higher-dosage administration has been optimized for fluoroquinolones, based on the theory that the area under the concentration-time curve (AUC)/MIC is closely associated with bactericidal activity (12, 13) . Although ciprofloxacin is usually taken 2 or 3 times a day based on the manufacturer's package insert, in fact Effects of the Fluoroquinolone Antibacterial Drug Ciprofloxacin on Ventricular Repolarization in the Halothane-Anesthetized Guinea Pig the recommended clinical daily dose of ciprofloxacin for this purpose is a once a day. However, information is limited regarding the electrophysiological effects of ciprofloxacin in the heart at higher dose ranges in vivo (14) . In this study, we precisely assessed the cardiac safety of ciprofloxacin using the halothane-anesthetized guinea pig by recording the monophasic action potential (MAP) of the ventricle (15 -17) . To better analyze the proarrhythmic potential of ciprofloxacin, we further assessed the electrophysiological effects of sparfloxacin and moxifloxacin; the former is a well-known QTprolonging drug, and the latter is used clinically as a positive control drug when conducting the thorough QT/QTc studies in healthy volunteers, on the basis of the ICH E14 guidelines (18) .
Materials and Methods
All experiments were approved by the Ethics Committee of Toho University and performed in accordance with the Guiding Principles for the Care and Use of Laboratory Animals approved by The Japanese Pharmacological Society. Thirty Hartley guinea pigs (Kiwa Laboratory Animals, Wakayama) were used in this study.
In vivo measurement of monophasic action potentials
Hemodynamic and electrophysiological parameters were measured under halothane anesthesia as described previously (16, 17) . Hartley guinea pigs, weighing about 400 g, were initially anesthetized with sodium thiopental (40 mg/kg, i.p.). After a tracheal cannula was inserted, 1.0% halothane vaporized with 100% oxygen was supplied as an inhalant via a rodent ventilator (SN-480-7; Shinano, Tokyo). The tidal volume and respiratory rate were set at 10 ml/kg and 60 strokes/min, respectively, and body temperature was maintained at 37°C using a heating pad. The left jugular vein was cannulated for drug administration, and the left carotid artery was also cannulated for measurement of the blood pressure. The surface lead II ECG was obtained from the limb electrodes. The corrected QT interval (QTc) was calculated using Van de Water's formula [QTc(V) = QT − 0.087(RR − 1000)] (19) and Sakaguchi's formula [QTc(S) = QT / (RR/300) 1/3 ] (20), where a unit is given in ms. The latter formula has been established for halothane-anesthetized guinea pigs whose standard heart rate is 200 beats/min. A MAP recording/pacing combination catheter (3 F, inter-electrode distance 4 mm, SMC-304; Physio-Tech, Tokyo) was positioned at the right ventricle via the right jugular vein. The signals were amplified with a differential amplifier (DAM 50; World Precision Instruments, Sarasota, FL, USA). The duration of the monophasic action potential signals was measured as an interval, along a line horizontal to the diastolic baseline, from the monophasic action potential upstroke to the desired repolarization level. The interval (ms) at the 90% repolarization level was defined as the MAP 90 .
The heart was electrically driven with a stimulator (SEN-3301; Nihon Kohden, Tokyo) and an isolator (SS-104J, Nihon Kohden). The stimulation pulses were rectangular in shape, of 2 V (about twice the threshold voltage) and 3 ms in duration. The MAP 90 was measured during sinus rhythm (MAP 90(sinus) ) and at a pacing cycle length of 300 ms (MAP 90(CL300) ) or 250 ms (MAP 90(CL250) ). Cardiovascular parameters were monitored continuously with a polygraph system (RM-6000, Nihon Kohden) and analyzed with a real-time fully automatic analysis system (MP/VAS 3 for Windows ver 1.0, Physio-Tech).
For assessment of instability of the ventricular repolarization, the MAP duration (MAP 90 ) of 51 consecutive beats under sinus rhythm was measured before and after drug administration. Poincaré plots of MAP 90 (n) vs. MAP 90 (n + 1) were prepared for each analytical time point. The mean orthogonal distance from the diagonal to the points of the Poincaré plot was determined as short-term variability (=∑ | MAP 90 (n + 1) − MAP 90 (n) | / [50 ×√ 2]). On the other hand, the mean distance to the mean of the parameter parallel to the diagonal of the Poincaré plot was determined as longterm variability (=∑ | MAP 90 (n + 1) + MAP 90 (n) − 2MAP 90 (mean) | / [50 ×√2]), which has been applied when analyzing the relationship between the instability of ventricular repolarization and proarrhythmic potential in patients with long-QT syndrome and proarrhythmic animal models (21) .
The ECG parameters and MAP 90 were measured under sinus rhythm as the mean of three consecutive recordings. The MAP 90 during ventricular pacing was obtained at a cycle length of 300 and 250 ms as the mean of the values obtained from the three consecutive MAP recordings. After the basal control assessment (C), a dose of 3 mg/kg ciprofloxacin was infused over 10 min. The ECG parameters and MAP 90 were measured 5, 10, 15, 20, 25, and 30 min after the start of drug infusion. Next, 10 mg/kg ciprofloxacin was additionally infused over 10 min, and each parameter was measured in the same manner. Also, the effects of moxifloxacin or sparfloxacin at doses of 3 and 10 mg/kg were assessed in another series of animals.
Measurement of plasma drug concentrations
Using another series of guinea pigs under anesthesia, blood was withdrawn from the right carotid artery 10 and 30 min after the start of infusion of ciprofloxacin, moxifloxacin, or sparfloxacin at 3 or 10 mg/kg, and centrifuged at 1,500 × g for 30 min at 4°C to obtain the plasma. Plasma concentrations of the drugs were determined by high-performance liquid chromatography.
Drugs
Ciprofloxacin hydrochloride monohydrate (molecular weight = 385.82), moxifloxacin hydrochloride (molecular weight = 437.89), and sparfloxacin (molecular weight = 392.40) were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). They were dissolved in 0.5% lactic acid and administered intravenously at an infusion rate of 2 ml/kg per 10 min. The following drugs were purchased: thiopental sodium (Mitsubishi Tanabe Pharma, Osaka), halothane (Takeda Chemical Industries, Osaka), and heparin sodium (Ajinomoto Pharmaceuticals, Tokyo).
Statistical analysis
Data are presented as the mean ± S.E.M. Significance of differences for any given parameter was evaluated by one-way repeated-measures analysis of variance (ANOVA) followed by Dunnett's test. Differences at P < 0.05 were considered significant.
Results
The plasma concentrations of ciprofloxacin, moxifloxacin and sparfloxacin are summarized in Table 1 . The time courses of the effects of ciprofloxacin (n = 6), moxifloxacin (n = 6), and sparfloxacin (n = 6) on the heart rate are summarized in Fig. 1 . In the ciprofloxacin group, the pre-drug control heart rate was 201 ± 2 beats/min. No significant change was detected in the heart rate after administration of a low dose of 3 mg/kg. A high dose of 10 mg/kg decreased the heart rate, and significant changes were detected for 25 -30 min. In the moxifloxacin group, the pre-drug control heart rate was 206 ± 3 beats/min. No significant change in the heart rate was detected after the low dose of 3 mg/kg, and the high dose of 10 mg/kg decreased the heart rate for 5 -30 min. In the sparfloxacin group, the predrug control heart rate was 203 ± 3 beats/min. The low dose of 3 mg/kg decreased the heart rate at 10 min, and the high dose of 10 mg/kg decreased the heart rate for 5 -30 min.
Typical tracings of the effects of ciprofloxacin on the ECG are shown in Fig. 2 , whereas the time courses of the effects of ciprofloxacin, moxifloxacin, and sparfloxacin on ECG parameters are summarized in Blood was withdrawn from the right carotid artery 10 and 30 min after the start of 3-or 10-mg/kg infusion of each drug. Data are presented as the mean ± S.E.M. (n = 4).
Fig. 1.
Time courses of the effects of ciprofloxacin (n = 6), moxifloxacin (n = 6), and sparfloxacin (n = 6) on heart rate (HR). Data are presented as the mean ± S.E.M. The solid symbols represent significant differences from the corresponding pre-drug control value (C) for each parameter at P < 0.05. Fig. 3 . In the ciprofloxacin group, pre-drug control values of the PR interval, QRS width, QT interval, QTc(V), and QTc(S) were 65 ± 3, 26 ± 1, 180 ± 7, 241 ± 7, and 180 ± 7 ms, respectively. After the low dose, no significant change was detected in the ECG parameters. The high dose increased the PR interval for 5 -30 min; the QRS width at 5, 10, and 30 min; the QT interval for 10 -30 min; and the QTc(V) and QTc(S) for 15 -30 min. In the moxifloxacin group, the pre-drug control values of the PR interval, QRS width, QT interval, QTc(V), and QTc(S) were 59 ± 2, 40 ± 2, 181 ± 4, 243 ± 4, and 184 ± 4 ms, respectively. After administration of the low dose, no significant change was detected in the ECG parameters, whereas the high dose increased the QT interval, QTc(V), and QTc(S) for 5 -30 min. Meanwhile, no significant change was detected in the PR interval or QRS width. In the sparfloxacin group, the pre-drug control values of the PR interval, QRS width, QT interval, QTc(V), and QTc(S) were 62 ± 2, 29 ± 2, 184 ± 1, 246 ± 1, and 188 ± 3 ms, respectively. The low dose increased the QT interval, QTc(V), and QTc(S) for 5 -30 min, and the high dose further increased all three parameters for 5 -30 min. Meanwhile, no significant change was detected in the PR interval or QRS width. Typical tracings of the effects of ciprofloxacin on the monophasic action potential are depicted in Fig. 2 . The time courses of the effects of ciprofloxacin, moxifloxacin, and sparfloxacin on the MAP 90(sinus) , MAP 90(CL300) , and MAP 90(CL250) are summarized in Fig. 4 . In the ciprofloxacin group, pre-drug control values of the MAP 90(sinus) , MAP 90(CL300) , and MAP 90(CL250) were 157 ± 8, 162 ± 8 and 153 ± 7 ms, respectively. The low 3 . Time courses of the effects of ciprofloxacin (n = 6), moxifloxacin (n = 6), and sparfloxacin (n = 6) on ECG parameters: PR interval (triangles), QRS width (squares), QT interval (circles), and QTc (diamonds: Sakaguchi, inverted triangles: Van de Water). Data are presented as the mean ± S.E.M. The maximum changes in the QT interval after the low dose of ciprofloxacin, moxifloxacin, and sparfloxacin were 5 ± 2, 12 ± 6, and 26 ± 2 ms, respectively, whereas those after the high dose were 11 ± 2, 30 ± 3, and 66 ± 5 ms, respectively. The solid symbols represent significant differences from the corresponding pre-drug control value (C) for each parameter at P < 0.05. Table 2 summarizes the short-term and long-term variability of the MAP 90 before and after drug administration. Sparfloxacine significantly increased both the short-term and long-term variability. Fig. 4 . Time courses of the effects of ciprofloxacin (n = 6), moxifloxacin (n = 6), and sparfloxacin (n = 6) on the duration of the monophasic action potential at a level of 90% repolarization during sinus rhythm (MAP90(sinus), circles) and that during ventricular pacing at a cycle length of 300 ms (MAP90(CL300), square) and 250 ms (MAP90(CL250), triangles). Data are presented as the mean ± S.E.M. The solid symbols represent significant differences from the corresponding pre-drug control value (C) for each parameter at P < 0.05. Fig. 5 . Effects of ciprofloxacin, moxifloxacin, and sparfloxacin on the Poincaré plots of the duration of the monophasic action potential (MAP90) in the halothane-anesthetized guinea pig. Fifty-one beats were plotted for each of three analytic time points. STV: short-term variability, LTV: long-term variability.
Discussion
The present study showed that intravenous administration of ciprofloxacin at 10 mg/kg prolonged the ventricular repolarization phase together with delays of both atrioventricular and intraventricular conduction in the present halothane-anesthetized guinea-pig model. The reported peak plasma concentrations (C max ) of ciprofloxacin, moxifloxacin, and sparfloxacin in humans are 2.5 -3.3, 2.5, and 0.6 mg/ml, respectively (22) . Thus, the concentrations of ciprofloxacin and moxifloxacin used in the present study are considered to have been within the therapeutic to supra-therapeutic dose ranges, whereas the doses of sparfloxacin were within the supratherapeutic dose ranges.
Halothane anesthesia has been recognized to reduce the repolarization reserve of the ventricle via inhibition of cardiac ion channels, such as I Kr or a slow component of delayed rectifier K + channels (I Ks ), allowing sufficient sensitivity for detection of drugs suspected to prolong the QT interval (15, 23) . In this study, moxifloxacin at 3 mg/kg slightly prolonged the QT interval by 12 ms with a C max value of 3.5 mg/ml. In the previous thorough QT/QTc studies in healthy volunteers, QTc was increased by 12 -15 ms after oral administration of 400 mg moxifloxacin, and the C max was 2.1 -2.3 mg/ml (24, 25) . Therefore, the halothane-anesthetized guinea-pig model is thought to be sufficiently sensitive for detection of drug-induced QT-interval prolongation relative to that in healthy humans. Another clinical study has shown that oral administration of sparfloxacin at 200 mg increased the QTc by 15 ms in healthy volunteers (26) , apparently corresponding approximately to the results obtained for low-dose sparfloxacin in the present study. These observations suggest that the current animal model is applicable for detection of QT-interval prolongation induced by fluoroquinolone antibiotics.
Here we found that ciprofloxacin at 3 mg/kg slightly increased the MAP duration together with induction of modest bradycardia. Meanwhile, no significant changes in the MAP duration were detected during constant ventricular pacing. Therefore, the statistically significant changes in MAP duration during sinus rhythm may be attributable mainly to decreased heart rate. Ciprofloxacin at 10 mg/kg significantly prolonged the QT interval to an extent comparable to that induced by moxifloxacin at 3 mg/kg. Meanwhile, the PR interval and QRS width were also increased after administration of ciprofloxacin at the high dose, suggesting that the drug inhibited cardiac K + channels as well as Na + and Ca 2+ channels in vivo. At present, no published patch-clamp data showing that ciprofloxacin blocks Na + and Ca 2+ channels are available. In a previous study, ciprofloxacin inhibited hERG K + currents with an IC 50 of 335 mM (111 mg/ml) (7), which is about 8 times higher than the C max after a high dose of ciprofloxacin (14.24 mg/ml (43 mM)). However, in that study, the slope of the concentration-response curve for hERG inhibition was less steep, and about 30% inhibition was observed at a concentration around the C max for high-dose ciprofloxacin, which may partly explain the relationship between the ciprofloxacin-induced QT-interval prolongation and its inhibitory action on hERG K + channels. The short-term variability of the ventricular repolarization period is a well-established predictive marker of proarrhythmia, and increment of the short-term vari ability is recognized to show greater beat-to-beat variability of ventricular repolarization, reflecting the premonitory phenomenon of early afterdepolarization (27) . Notably, this parameter demonstrates the torsadogenic potential of QT-prolonging drugs, even those with multi-ion channel-blocking action, such as amiodarone, bepridil, and terfenadine (21, 28) . In the present study, ciprofloxacin and moxifloxacin hardly affected the short-term variability of MAP duration, in contrast to the high dose of sparfloxacin, suggesting that the drugs may not affect the instability of ventricular repolarization within the dose ranges currently employed. However, caution needs to be drawn to a possibility of proarrhythmia induced by ciprofloxacin, especially in patients with cardiac conduction disturbance, since in this study ciprofloxacin had a suppressive action on The parameters were measured at 30 min in the ciprofloxacin group and at 10 min in the moxifloxacin and sparfloxacin groups. STV, short-term variability of MAP90; LTV, long-term variability of MAP90. Data are presented as the mean ± S.E.M (n = 6). *P < 0.05, **P < 0.01, compared with corresponding control values.
ventricular conduction (widening of the QRS width) at the high dose, which may occasionally become a cause of proarrhythmia such as reentry or conduction block in animal models of myocardial infarction (29) . Recently, a higher dosage of fluoroquinolones has been optimized for preventing the emergence of resistance. Based on the present results and previous clinical information, when the clinically recommended daily dose of ciprofloxacin, which has usually been taken 2 or 3 times a day, is administered according to the once-daily dosing regimen, a similar degree of caution to that in patients taking moxifloxacin at 400 mg is necessary.
In conclusion, ciprofloxacin exerted a multi-ion channel-blocking action in the heart within a supratherapeutic dose range. Therefore, careful observation may be necessary for patients with heart disease receiving a higher dose of ciprofloxacin in order to prevent the emergence of resistance.
